Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) have earned an average recommendation of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $26.6667.

Several equities research analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a research note on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research note on Tuesday, April 21st. TD Cowen reaffirmed a “buy” rating on shares of Nanobiotix in a research note on Thursday, March 12th. Guggenheim raised their price target on shares of Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, April 2nd. Finally, UBS Group raised their price target on shares of Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st.

Nanobiotix Price Performance

Shares of NASDAQ NBTX opened at $49.48 on Tuesday. Nanobiotix has a 52 week low of $3.64 and a 52 week high of $57.14. The company’s 50-day moving average price is $35.36 and its 200 day moving average price is $27.04.

Nanobiotix (NASDAQ:NBTX) last released its quarterly earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share (EPS) for the quarter. The business had revenue of $3.42 million for the quarter. Equities research analysts forecast that Nanobiotix will post 0.53 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Royal Bank of Canada lifted its holdings in shares of Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after acquiring an additional 2,500 shares during the period. Optiver Holding B.V. purchased a new position in shares of Nanobiotix during the 3rd quarter worth about $101,000. Marshall Wace LLP purchased a new position in shares of Nanobiotix during the 4th quarter worth about $220,000. Finally, Millennium Management LLC purchased a new position in shares of Nanobiotix during the 4th quarter worth about $390,000. 38.81% of the stock is currently owned by hedge funds and other institutional investors.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.